Although the above described signaling pathways are exciting; they will however require, further stringent analysis to determine whether genetic lesions/mutations/sustained activation occur per se in RAC1/PAK1/FAK/SHP2 molecules in neoplastic MCs found in mastocytosis patients. This evidence concerns the gene PTPN11 and mastocytosis.